Industries > Pharma > Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies
Back to Pharma Reports

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies

PUBLISHED: 21 May 2014
PAGES: 217
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: N/A Categories: ,

Osteoporosis drugs – new study showing you trends, R&D progress, and predicted revenues
Where’s the osteoporosis drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 217-page report provides 132 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT, PESTEL and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
– Dr. Karl Grindulis, Consultant Rheumatologist, Sandwell General Hospital, West Bromwich, UK
– Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these three submarkets and their respective segments:
• Antiresorptive Drugs
– Bisphosphonates
– Selective Oestrogen Receptor Modulators (SERMs)
– RANKL Antibodies
– Cathepsin K Inhibitors
– Other antiresorptive drugs
• Anabolic Drugs
– Human Recombinant Parathyroid Hormones
– Anti-Sclerostin monoclonal antibodies
• Other osteoporosis treatments

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 10 products, including these:
• Forteo
• Evista
• Prolia
• Actonel/Atelvia
• Fosamax
• Reclast/Aclasta
• Boniva

Our study also provides sales forecasts to 2024 for the following drugs which are currently in development:
• Duavee
• Odanacatib
• Romosozumab

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• South Korea
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, Brazil, China, Russia and South Korea in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for osteoporosis drugs will reach $8.36bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for osteoporosis drugs, expanding healthcare coverage, and the success of biological drugs will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• Eli Lilly
• Amgen
• GSK
• Merck
• Pfizer
• Novartis
• Sanofi
• Actavis

In general, a company profile gives you the following information:
• Revenue forecast for osteoporosis drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the osteoporosis drugs industry?
Our new report discusses issues and events affecting the osteoporosis drugs market. You will find discussions, including qualitative analyses:
• A global aging population
• Increasing awareness of osteoporosis and bone health education
• Expected launch of innovative therapies
• Increasing funds for R&D and clinical development
• Patent expirations of leading drugs
• Increasing generic competition
• Stringent regulation in key national markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies report helps you

In summary, our 217-page report gives you the following knowledge:
• Revenues forecast to 2024 for the world osteoporosis drugs market, 3 submarkets and 7 distinctive segments – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets – US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, South Korea and Rest of the World
• Assessment of 8 leading companies – hear about products, results and strategies including revenue forecasts for osteoporosis drugs to 2024
• Predicted revenues of 7 leading marketed osteoporosis drugs and 3 pipeline drugs to 2024 – see potentials of top products
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the osteoporosis drugs market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies


Download sample pages

Complete the form below to download your free sample pages for Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies


Connect with us

Visiongain Pharma

Visiongain Pharma

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories